Role of erlotinib in the management of pancreatic cancer

References

• AbbasRFettnerSRiekMA drug-drug interaction study to evaluate the effect of rifampicin on the pharmacokinetics of the EGF receptor tyrosine kinase inhibitor, erlotinib, in healthy subjects [abstract]Proc Am Soc Clin Oncol200322548
   Google Scholar
• AkitaRWSliwkowskiMXPreclinical studies with erlotinib (Tarceva)Semin Oncol2003303 Suppl 7152412840797
   PubMed Web of Science ®Google Scholar
• AlbanellJRojoFAverbuchSPharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD-1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibitionJ Clin Oncol2002201102411773160
   PubMed Web of Science ®Google Scholar
• AmadorMLOppenheimerDPereaSAn epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitorsCancer Res20046491394315604284
   PubMed Web of Science ®Google Scholar
• ArteagaCLThe epidermal growth factor receptor: from mutant oncogene in nonhuman cancers to therapeutic target in human neoplasiaJ Clin Oncol20011918 Suppl32S-40S
   PubMed Web of Science ®Google Scholar
• ArteagaCTargeting HER1/EGFR: a molecular approach to cancer therapySemin Oncol2003303 Suppl 7314
   Web of Science ®Google Scholar
• BaselgaJSkin as a surrogate tissue for pharmacodynamic end points: is it deep enough?Clin Cancer Res2003923899012855608
   PubMed Web of Science ®Google Scholar
• BondarVMSweeney-GotschBAndreeffMInhibition of the phosphatidylinositol 3'-kinase-AKT pathway induces apoptosis in pancreatic carcinoma cells in vitro and in vivoMol Cancer Ther200219899712481421
   PubMed Web of Science ®Google Scholar
• BramhallSRRosemurgyABrownPDMarimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trialJ Clin Oncol20011934475511481349
   PubMed Web of Science ®Google Scholar
• BramhallSRSchulzJNemunaitisJA double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancerBr J Cancer200287161712107836
   PubMed Web of Science ®Google Scholar
• BrunsCJHarbisonMTDavisDWEpidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanismsClin Cancer Res2000619364810815919
   PubMed Web of Science ®Google Scholar
• BurrisHAIIIMooreMJAndersenJImprovements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trialJ Clin Oncol1997152403139196156
   PubMed Web of Science ®Google Scholar
• ChevertonPFriessHAndrasCPhase III results of exatecan (DX-8951f) versus gemcitabine in chemotherapy-naive patients with advanced pancreatic cancer [abstract]Proc Am Soc Clin Oncol2004234005
   Google Scholar
• CiardielloFBiancoRDamianoVAntiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cellsClin Cancer Res2000637394710999768
   PubMed Web of Science ®Google Scholar
• CiardielloFCaputoRBiancoRAntitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitorClin Cancer Res2000620536310815932
   PubMed Web of Science ®Google Scholar
• CunninghamDChauIStockenDPhase III randomised comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancerEur J Cancer2005312
   Google Scholar
• DesaiBHigginsBSmithMAntitumour activity of the EGFR/TK inhibitor Tarceva (erlotinib, OSI-774) tumour models [abstract]Eur J Cancer200238203
   Web of Science ®Google Scholar
• DragovichTPatnaikARowinskyEKA phase I B trial of gemcitabine and erlotinib HCL in patients with advanced pancreatic adenocarcinoma and other potentially responsive malignancies [abstract]Proc Am Soc Clin Oncol200322223
   Google Scholar
• EberhardDAJohnsonBEAmlerLCMutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinibJ Clin Oncol2005235900916043828
   PubMed Web of Science ®Google Scholar
• EbertMPFeiGSchandlLReduced PTEN expression in the pancreas overexpressing transforming growth factor-beta 1Br J Cancer2002862576211870516
   PubMed Web of Science ®Google Scholar
• GatzemeierUPluzanskaASzczesnaAResults of a phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine (GC) chemotherapy in advanced non-small cell lung cancer (NSCLC) [abstract]J Clin Oncol20042214S7010
   Google Scholar
• GuttridgeDCAlbaneseCReutherJYNF-KappaB controls cell growth and differentiation through transcriptional regulation of cyclin D1Mol Cell Biol19991957859910409765
   PubMed Web of Science ®Google Scholar
• HabibAAChatterjeeSParkSKThe epidermal growth factor receptor engages receptor interacting protein and nuclear factor-kappa B (NF-Kappa B)-inducing kinase to activate NF-kappa B. Identification of a novel receptor-tyrosine kinase signalosomeJ Biol Chem200127688657411116146
   PubMed Web of Science ®Google Scholar
• HansenLAAlexanderNHoganMEGenetically null mice reveal a central role for epidermal growth factor receptor in the differentiation of the hair follicle and normal hair developmentAm J Pathol19971501959759176390
   PubMed Web of Science ®Google Scholar
• HeiserPWHebrokMDevelopment and cancer: lessons learned in the pancreasCell Cycle20043270214726662
   PubMed Web of Science ®Google Scholar
• HerbstRSErlotinib (Tarceva): an update on the clinical trial programSemin Oncol2003303 Suppl 7344612840799
   PubMed Web of Science ®Google Scholar
• HerbstRSJohnsonDHMininbergEPhase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancerJ Clin Oncol20052325445515753462
   PubMed Web of Science ®Google Scholar
• HerbstRSPragerDHermannRTRIBUTE: a Phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancerJ Clin Oncol2005235892916043829
   PubMed Web of Science ®Google Scholar
• HerrmannRBodokyGRuhstallerTGemcitabine (G) plus Capecitabine (C) versus G alone in locally advanced or metastatic pancreatic cancer. A randomized phase III study of the Swiss Group for Clinical Cancer Research (SAKK) and the Central European Cooperative Oncology Group (CECOG) [abstract]J Clin Oncol20052316S4010
   Google Scholar
• HidalgoMBloedowDPharmacokinetics and pharmacodynamics: maximizing the clinical potential of erlotinib (Tarceva)Semin Oncol2003303 Suppl 7253312840798
   PubMed Web of Science ®Google Scholar
• HidalgoMSiuLLNemunaitisJPhase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignanciesJ Clin Oncol20011932677911432895
   PubMed Web of Science ®Google Scholar
• HinzMKrappmannDEichtenANF-kappaB function in growth control: regulation of cyclin D1 expression and G0/G1-to-S-phase transitionMol Cell Biol1999192690810082535
   PubMed Web of Science ®Google Scholar
• HortobagyiGNSauterGChallenges and opportunities for erlotinib (Tarceva): what does the future hold?Semin Oncol2003303 Suppl 7475312840800
   PubMed Web of Science ®Google Scholar
• JungYDMansfieldPFAkagiMEffects of combination anti-vascular endothelial growth factor receptor and anti-epidermal growth factor receptor therapies on the growth of gastric cancer in a nude mouse modelEur J Cancer20023811334012008203
   PubMed Web of Science ®Google Scholar
• KingLEJrGatesREStoscheckCMThe EGF/TGF alpha receptor in skinJ Invest Dermatol1990946 Suppl164S-70S
   Web of Science ®Google Scholar
• LauxIJainASinghSEpidermal growth factor receptor dimerization status determines skin toxicity to HER-kinase targeted therapiesBr J Cancer200694859216306877
   PubMed Web of Science ®Google Scholar
• LemoineNRHughesCMBartonCMThe epidermal growth factor receptor in human pancreatic cancerJ Pathol19921667121538276
   PubMed Web of Science ®Google Scholar
• LoRussoPMPhase I Studies of ZD1839 in patients with common solid tumorsSemin Oncol2003301 Suppl 121912644981
   PubMed Web of Science ®Google Scholar
• LouvetCLabiancaRHammelPGemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD Phase III TrialJ Clin Oncol20052335091615908661
   PubMed Web of Science ®Google Scholar
• LynchTJBellDWSordellaRActivating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinibN Engl J Med200435021293915118073
   PubMed Web of Science ®Google Scholar
• MalikSNSiuLLRowinskyEKPharmacodynamic evaluation of the epidermal growth factor receptor inhibitor OSI-774 in human epidermis of cancer patientsClin Cancer Res2003924788612855621
   PubMed Web of Science ®Google Scholar
• MarmorMDSkariaKBYardenYSignal transduction and oncogenesis by ErbB/HER ReceptorsInt J Radiat Oncol Biol Phys2004589031314967450
   PubMed Web of Science ®Google Scholar
• MendelsohnJBaselgaJStatus of epidermal growth factor receptor antagonists in the biology and treatment of cancerJ Clin Oncol20032127879912860957
   PubMed Web of Science ®Google Scholar
• MitaCASchwartzGMitaMMA pilot, pharmacokinetic (PK), and pharmacodynamic (PD) study to determine the feasibility of intrapatient dose escalation to tolerable rash and the activity of maximal doses of erlotinib (E) in previously treated patients with advanced non-small cell lung cancer (NSCLC) [abstract]J Clin Oncol20052316S3045
   Google Scholar
• MiyamotoYMaitraAGhoshBNotch mediates TGF alpha-induced changes in epithelial differentiation during pancreatic tumorigenesisCancer Cell200335657612842085
   PubMed Web of Science ®Google Scholar
• MooreMJHammJDanceyJComparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12–9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: a Phase III Trial of the National Cancer Institute of Canada Clinical Trials GroupJ Clin Oncol200321329630212947065
   PubMed Web of Science ®Google Scholar
• MooreMJGoldsteinDHammJErlotinib plus gemcitabine compared to gemcitabine alone in patients with advanced pancreatic cancer. A phase III trial of the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG) [abstract]J Clin Oncol2005236S115545667
   PubMedGoogle Scholar
• MoyerJDBarbacciEGIwataKKInduction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinaseCancer Res1997574838489354447
   PubMed Web of Science ®Google Scholar
• NgSSTsaoMSNickleeTEffects of the epidermal growth factor receptor inhibitor OSI-774, tarceva, on downstream signaling pathways and apoptosis in human pancreatic adenocarcinomaMol Cancer Ther200217778312492110
   PubMed Web of Science ®Google Scholar
• OgisoHIshitaniRNurekiOCrystal structure of the complex of human epidermal growth factor and receptor extracellular domainsCell20021107758712297050
   PubMed Web of Science ®Google Scholar
• OverholserJPPrewettMCHooperATEpidermal growth factor receptor blockade by antibody IMC-C225 inhibits growth of a human pancreatic carcinoma xenograft in nude miceCancer200089748210897003
   PubMed Web of Science ®Google Scholar
• Perez-SolerRSaltzLCutaneous adverse effects With HER1/EGFR-targeted agents: is there a silver lining?J Clin Oncol20052352354616051966
   PubMed Web of Science ®Google Scholar
• PerrenAKomminothPSaremaslaniPMutation and expression analyses reveal differential subcellular compartmentalization of PTEN in endocrine pancreatic tumors compared to normal islet cellsAm J Pathol2000157109710311021813
   PubMed Web of Science ®Google Scholar
• PollackVASavageDMBakerDAInhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: dynamics of receptor inhibition in situ and antitumor effects in athymic miceJ Pharmacol Exp Ther19992917394810525095
   PubMed Web of Science ®Google Scholar
• PorterfieldBWDragovichTPatnaikAErlotinib + gemcitabine in patients with unresectable pancreatic carcinoma: Results from a phase IB trial [abstract]J Clin Oncol20042214S4110
   Google Scholar
• RatainMJGeorgeCMJanischLPhase I trial of erlotinib (OSI-774) in combination with gemcitabine (G) and cisplatin (P) in patients with advanced solid tumors [abstract]Proc Am Soc Clin Oncol2002212115
   Web of Science ®Google Scholar
• RichardsDAKindlerHLOettleHA randomized phase III study comparing gemcitabine plus pemetrexed versus gemcitabine in patients with locally advanced or metastatic pancreatic cancer [abstract]Proc Am Soc Clin Oncol2004234007
   Google Scholar
• Rocha LimaCMGreenMRRotcheRIrinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rateClin Oncol200422377683
   Google Scholar
• RuggeriBAHuangLWoodMAmplification and overexpression of the AKT2 oncogene in a subset of human pancreatic ductal adenocarcinomasMol Carcinog1998218169496907
   PubMed Web of Science ®Google Scholar
• SchliemanMGFahyBNRamsamoojRIncidence, mechanism and prognostic value of activated AKT in pancreas cancerBr J Cancer20038921101514647146
   PubMed Web of Science ®Google Scholar
• SegaertSVan CutsemEClinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitorsAnn Oncol20051614253316012181
   PubMed Web of Science ®Google Scholar
• ShepherdFAPereiraJCiuleanuTEA randomized placebo-controlled trial of erlotinib in patients with advanced non-small cell lung cancer (NSCLC) following failure of 1st line or 2nd line chemotherapy. A National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG) trial [abstract]J Clin Oncol20042214S7022
   Google Scholar
• SirotnakFMZakowskiMFMillerVAEfficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinaseClin Cancer Res2000648859211156248
   PubMed Web of Science ®Google Scholar
• SoulieresDSenzerNNVokesEEMulticenter Phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neckJ Clin Oncol200422778514701768
   PubMed Web of Science ®Google Scholar
• TemperoMPlunkettWRuiz Van HaperenVRandomized Phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinomaJ Clin Oncol2003213402812885837
   PubMed Web of Science ®Google Scholar
• Van CutsemEvan de VeldeHKarasekPPhase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancerJ Clin Oncol2004221430815084616
   PubMed Web of Science ®Google Scholar
• WangWAbbruzzeseJLEvansDBThe nuclear factor-kappa B RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cellsClin Cancer Res19995119279918209
   PubMed Web of Science ®Google Scholar
• YamanakaYFriessHKobrinMSOverexpression of HER2/neu oncogene in human pancreatic carcinomaHum Pathol1993241127348104858
   PubMed Web of Science ®Google Scholar
• YardenYSliwkowskiMXUntangling the ErbB signalling networkNat Rev Mol Cell Biol200121273711252954
   PubMed Web of Science ®Google Scholar